241 related articles for article (PubMed ID: 21565788)
1. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH.
Tala H; Robbins R; Fagin JA; Larson SM; Tuttle RM
J Clin Endocrinol Metab; 2011 Jul; 96(7):2105-11. PubMed ID: 21565788
[TBL] [Abstract][Full Text] [Related]
2. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
[TBL] [Abstract][Full Text] [Related]
4. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.
Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
Thyroid; 2012 Mar; 22(3):310-7. PubMed ID: 22313411
[TBL] [Abstract][Full Text] [Related]
5. Recombinant Thyrotropin vs Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod).
Leenhardt L; Leboulleux S; Bournaud C; Zerdoud S; Schvartz C; Ciappuccini R; Kelly A; Morel O; Dygai-Cochet I; Rusu D; Chougnet CN; Lion G; Eberlé-Pouzeratte MC; Catargi B; Kabir-Ahmadi M; Le Peillet Feuillet E; Taïeb D
J Clin Endocrinol Metab; 2019 Apr; 104(4):1020-1028. PubMed ID: 30398518
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
[TBL] [Abstract][Full Text] [Related]
7. Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.
Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
Endocr Pract; 2013; 19(1):139-48. PubMed ID: 23186979
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of Recombinant Human TSH as a Preparation for Radioiodine Therapy in Patients with Distant Metastases from Papillary Thyroid Cancer: Comparison of Long-Term Survival Outcomes with Thyroid Hormone Withdrawal.
Tsai HC; Ho KC; Chen SH; Tseng JR; Yang LY; Lin KJ; Cheng JC; Liou MJ
Diagnostics (Basel); 2022 Jan; 12(1):. PubMed ID: 35054388
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
Ma C; Xie J; Liu W; Wang G; Zuo S; Wang X; Wu F
Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD008302. PubMed ID: 21069705
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b).
Rosario PW; Mourão GF; Calsolari MR
Arch Endocrinol Metab; 2017; 61(2):167-172. PubMed ID: 28226001
[TBL] [Abstract][Full Text] [Related]
12. Recombinant or endogenous thyroid-stimulating hormone for radioactive iodine therapy in thyroid cancer: state of knowledge and current controversies.
Coerts HI; de Keizer B; Marlowe RJ; Verburg FA
Eur J Endocrinol; 2023 Feb; 188(2):. PubMed ID: 36655579
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer.
Handkiewicz-Junak D; Gawlik T; Rozkosz J; Puch Z; Michalik B; Gubala E; Krajewska J; Kluczewska A; Jarzab B
Eur J Endocrinol; 2015 Dec; 173(6):873-81. PubMed ID: 26423095
[TBL] [Abstract][Full Text] [Related]
14. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in
Plyku D; Hobbs RF; Huang K; Atkins F; Garcia C; Sgouros G; Van Nostrand D
J Nucl Med; 2017 Jul; 58(7):1146-1154. PubMed ID: 28104741
[TBL] [Abstract][Full Text] [Related]
15. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons.
Freudenberg LS; Jentzen W; Petrich T; Frömke C; Marlowe RJ; Heusner T; Brandau W; Knapp WH; Bockisch A
Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2267-76. PubMed ID: 20661558
[TBL] [Abstract][Full Text] [Related]
16. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer in children, adolescents and young adults.
Schumm MA; Pyo HQ; Kim J; Tseng CH; Yeh MW; Leung AM; Chiu HK
Clin Endocrinol (Oxf); 2021 Aug; 95(2):344-353. PubMed ID: 33704813
[TBL] [Abstract][Full Text] [Related]
18. The effect of lithium on the progression-free and overall survival in patients with metastatic differentiated thyroid cancer undergoing radioactive iodine therapy.
Luo H; Tobey A; Auh S; Cochran C; Zemskova M; Reynolds J; Lima C; Burman K; Wartofsky L; Skarulis M; Kebebew E; Klubo-Gwiezdzinska J
Clin Endocrinol (Oxf); 2018 Oct; 89(4):481-488. PubMed ID: 29972703
[TBL] [Abstract][Full Text] [Related]
19. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
Vrachimis A; Schober O; Riemann B
Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
[TBL] [Abstract][Full Text] [Related]
20. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
